Acadia Pharma Insider Buying Signals Confidence in CNS Pipeline & Future Growth
Insider buys and RSUs signal confidence in Acadia’s CNS pipeline, suggesting a 2026‑2027 upside as Parkinson’s and schizophrenia trials mature.
5 minutes to read
ACADIA PHARMACEUTICALS INC
ACADIA Insider Sales: Small Trades, Big Focus on Pipeline & Market Access
Insider sales at ACADIA reveal no major valuation shifts—focus on pipeline milestones, regulatory progress and market access instead.
3 minutes to read
Acadia Pharma Insider Buying Signals Confidence in CNS Pipeline & Investors’ Bullish Outlook
Acadia Pharmaceuticals’ insider buying signals confidence in its CNS drug pipeline and upcoming FDA review, offering investors a bullish outlook amid solid valuation metrics.
4 minutes to read
ACADIA CEO’s Insider Moves Show Confidence: Zero-Cost Buy and RSU Sale in March 2026
CEO’s ACADIA insider moves: zero‑cost stock buys and RSU sales reveal confidence amid a 3.57% weekly price rise, signaling strategic liquidity and long‑term ownership.
4 minutes to read
Acadia CFO’s Insider Trades Signal Optimism Ahead of Parkinson’s & Schizophrenia Phase 3 Milestones
Acadia CFO’s recent insider trades reveal confidence in its late‑stage Parkinson’s and schizophrenia pipeline, RSU‑driven growth strategy, and analyst‑backed market‑access upside.
4 minutes to read
ACADIA Insider Buying: Rhodes’ 12,944 Shares Signal Strong Confidence Ahead of Q4 Earnings
ACADIA insider Jennifer Rhodes buys 12,944 shares via RSUs, boosting her stake and signaling confidence ahead of Feb 25 earnings and CNS pipeline progress.
3 minutes to read